Item 2.02. Results of Operations and Financial Condition.



On November 10, 2021, Recursion Pharmaceuticals, Inc. issued a press release
announcing its results of operations and financial condition for the third
quarter ended September 30, 2021. A copy of the press release is furnished as
Exhibit 99.1 and is incorporated herein by reference.


Item 7.01. Regulation FD Disclosure.
On November 10, 2021, Recursion Pharmaceuticals, Inc. released an updated
investor presentation. The investor presentation will be used from time to time
in meetings with investors. A copy of the presentation is attached hereto as
Exhibit 99.2.

The information furnished pursuant to Item 2.02 (including Exhibit 99.1) and
7.01 (including Exhibit 99.2) on this Form 8-K, shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference into any other filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit Number              Description
                              Press release issued by Recursion Pharmaceuticals, Inc. dated
99.1                            November     1    0    , 2021
                              Investor presentation of Recursion Pharmaceuticals, Inc. dated November
99.2                        10, 2021
                            Cover Page Interactive Data File (embedded within the Inline XBRL
104                         document)

© Edgar Online, source Glimpses